DDInter172 DDInter489
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Deferiprone {u} (Compound) binds {v} (Gene) UGT1A6
Deferiprone {u} (Compound) upregulates {v} (Gene) BTK
Deferiprone {u} (Compound) is included by {v} (Pharmacologic Class) Iron Chelating Activity
Deferiprone {u} (Compound) downregulates {v} (Gene) HSPA8
Deferiprone {u} (Compound) causes {v} (Side Effect) Rash pustular
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium sulfate
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Deferiprone (Compound) binds UGT1A6 (Gene)
Deferiprone (Compound) upregulates BTK (Gene)
Deferiprone (Compound) is included by Iron Chelating Activity (Pharmacologic Class)
Deferiprone (Compound) downregulates HSPA8 (Gene)
Deferiprone (Compound) causes Rash pustular (Side Effect)
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Deferiprone may lead to a major life threatening interaction when taken with Tioguanine
Deferiprone may lead to a major life threatening interaction when taken with Rucaparib